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Abstract
Background: Colorectal cancer (CRC) is a major worldwide health problem due to its high prevalence and mortality
rate. T-cell intracellular antigen 1 (TIA1) is an important tumor suppressor involved in many aspects of carcinogenesis
and cancer development. How TIA1 expression is regulated during CRC development remains to be carefully elucidated.
Methods: In CRC tissue sample pairs, TIA1 protein and mRNA levels were monitored by Western blot and qRT-PCR,
respectively. Combining meta-analysis and miRNA target prediction software, we could predict microRNAs that
targeted TIA1. Next, three CRC cell lines (SW480, Caco2 and HT29) were used to demonstrate the direct targeting of
TIA1 by miR-19a. In addition, we investigated the biological effects of TIA1 inhibition by miR-19a both in vitro by CCK-8,
EdU, Transwell, Ki67 immunofluorescence and Colony formation assays and in vivo by a xenograft mice model.
Results: In colorectal cancer (CRC), we found that TIA1 protein, but not its mRNA, was downregulated. We
predicted that TIA1 was a target of miR-19a and validated that miR-19a binded directly to the 3’-UTR of TIA1
mRNA. miR-19a could promote cell proliferation and migration in CRC cells and accelerated tumor growth in
xenograft mice by targeting TIA1.
Conclusions: This study highlights an oncomiR role for miR-19a in regulating TIA1 in CRC and suggests that
miR-19a may be a novel molecular therapeutic target for CRC.
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Background
Colorectal cancer (CRC) is one of the most prevalent
malignant tumors, with high morbidity and mortality
worldwide. In the USA, CRC is currently the third most
common cancer type and the third leading cause of can-
cer-related death [1]. Although advances in screening and
treatment have improved the life expectancy of CRC pa-
tients in recent decades [2], CRC remains a major health
problem all over the world. Much more attention should
be given to the exact mechanisms contributing to the ini-
tiation and development of CRC.
Although there are many risk factors for CRC (including
obesity, smoking, dietary patterns, physical inactivity, and
genetic and epigenetic factors) [3–5], understanding the
molecular basis of individual susceptibility to colorectal
cancer and determining the factors that initiate the devel-
opment of the tumor, drive its progression and determine
its responsiveness or resistance to antitumor agents are
the most important tasks in the study of this disease [2].
Among the myriad CRC-related molecular factors, onco-
gene activation (e.g., KRAS and IGF1R) and tumor sup-
pressor gene silencing (e.g., APC and PDCD4) play vital
roles during CRC tumorigenesis [6–9]. T-cell intracellular
antigen 1 (TIA1) is an RNA binding protein and is linked
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to multiple biologic processes associated with RNA me-
tabolism, both in the nucleus and in the cytoplasm
[10]. TIA1 is thought to be a new member of the tumor
suppressor family [11], as TIA1 regulates, modulates
and/or interacts with many types of mRNA involved in
cancer cell proliferation, apoptosis, angiogenesis, inva-
siveness and metastasis as well as in immune evasion
[12–16]. For example, it has been reported that knock-
down of TIA1 triggers cell proliferation and invasion as
well as tumor growth [14]. Furthermore, TIA1 has been
found to regulate many oncogenes (e.g., RAB40B) to
inhibit cell proliferation [12]. Moreover, TIA1 can
promote cell apoptosis by regulating Fas alternative
splicing [17]. In CRC, TIA1 is also closely connected to
tumorigenesis. For example, TIA1 has been found to
regulate VEGF isoform expression, angiogenesis, tumor
growth and bevacizumab resistance in CRC [15]. More-
over, TIA1 can be used to supplement prognostic infor-
mation related to TNM stage and adjuvant therapy in
mismatch repair-proficient colorectal cancer patients
[16]. Because of the myriad of tumor suppressor func-
tions of TIA1, it is imperative that we elucidate the
mechanisms underlying how TIA1 is regulated during
tumorigenesis, especially in CRC.
MicroRNAs (miRNAs) are small (19–23 nucleotides)
non-coding RNA molecules [18] that act as endogenous
suppressors of gene expression by binding to the 3’-un-
translated region (3’-UTR) of target mRNAs to induce
translational repression or mRNA cleavage. Occasion-
ally, miRNAs may bind directly to coding sequence of
mRNAs or even function as activators of gene
expression by binding to the 5’-UTR of target mRNAs
[19–21]. As vital post-transcriptional regulators, miR-
NAs are involved in numerous physiological and patho-
logical processes, such as developmental timing [22],
hematopoietic cell differentiation [23], cell proliferation
[24], organ development [25] and tumorigenesis in par-
ticular [26, 27]. Many miRNAs are directly or indirectly
correlated with cancer genes and can function as either
tumor suppressor miRNAs or oncomiRs [27]. During
CRC initiation and progression, some miRNAs show a
significant alteration in their expression patterns and
influence CRC cell proliferation, invasion and apop-
tosis. Among these miRNAs, miR-19a is one of the
most important. miR-19a belongs to a well-known and
important miRNA family named mir-17-92 (also known
as oncomir-1) and is a miRNA polycistron with pleio-
tropic functions in cell survival, proliferation, differenti-
ation and angiogenesis [28–31]. miR-19a has been
reported to be significantly overexpressed in CRC [32].
Moreover, miR-19a has been found to be induced by
PRL-3 to promote the proliferation and metastasis of
CRC cells [33]. miR-19a can also enhance the invasion
and metastasis of CRC cells by targeting TG2 [34].
More importantly, miR-19a is associated with lymph
metastasis and mediates TNF-α-induced EMT in CRC
[32]. These studies have revealed an important onco-
genic role of miR-19a in CRC. However, the precise
molecular mechanism through which miR-19a influ-
ences CRC progression remains unknown.
In this study, we identified TIA1 as a direct target
gene of miR-19a in CRC. We also detected an inverse
correlation between miR-19a and TIA1 protein levels in
CRC tissues. Moreover, we provided evidence that miR-
19a can promote CRC cell proliferation and migration




CRC tissue and paired normal adjacent tissue samples
were acquired from patients undergoing a surgical pro-
cedure at the Affiliated Drum Tower Hospital of Nanjing
University Medical School (Nanjing, China). Both the
tumor and normal tissues were sent for histological ana-
lysis and diagnostic confirmation. Written consent was
obtained from all patients, and all protocols concerning
the use of patient samples in this study were approved
by the Ethics Committee of Nanjing University. Tissue
samples were immediately frozen in liquid nitrogen at
the time of surgery and stored at -80 °C. All experiments
were performed in accordance with The Code of Ethics
of the World Medical Association (Declaration of
Helsinki) and approved guidelines of the Nanjing
University. The clinical features of the patients are
listed in Additional file 1: Table S1.
Cell culture
The three human CRC cell lines SW480, Caco2 and
HT29 were purchased from the Shanghai Institute of
Biochemistry and Cell Biology, Chinese Academy of
Sciences (Shanghai, China). SW480 and HT29 cells
were cultured in RPMI-1640 (Gibco, Carlsbad, CA,
USA) supplemented with 10% fetal bovine serum (FBS,
Gibco) in a humidified incubator at 37 °C with 5% CO2.
Caco2 cells were cultured in DMEM (Gibco) supple-
mented with 10% FBS (Gibco) in a humidified incuba-
tor at 37 °C with 5% CO2.
Protein isolation and western blot
RIPA lysis buffer (Beyotime, Shanghai, China) with
freshly added PMSF (Beyotime, Shanghai, China) was
used to isolate protein from cells or tissues. Proteins
were separated by 10% SDS-PAGE (Bio-Rad). Anti-
bodies against TIA1, CMYC, PDCD4 and GAPDH were
purchased from Santa Cruz Biotechnology (sc-365349,
sc-40, sc-130545 and sc-25778, respectively; Santa
Cruz, CA, USA).
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Meta-analysis of miRNA expression in CRC
We used an online database YM500 to analyze and
compare the miRNA expression in colon cancer tissues
and normal solid tissues. This database compared the
miRNA expression profiles between 8 normal solid
colon tissues and 429 primary solid colon tumors, and a
total of 2578 miRNAs were analyzed. In total, 273 miR-
NAs were found to be significantly changed in the solid
tumors compared to the normal tissues (128 were up-
regulated, and 145 were downregulated, Additional file
2: Table S2). Among the 128 upregulated miRNAs, 26
miRNAs were determined to be upregulated by an infin-
ite fold change at an extremely low expression level in
the normal group of these miRNAs. For these miRNAs,
we set a threshold of 26.18 for the base mean of the pri-
mary solid tumors, which was the average value of the
base means of these miRNAs. Above this threshold, we
found 7 significantly upregulated miRNAs, and miR-19a
ranked first among them. For the remainder of the 102
upregulated miRNAs, we set a threshold of 42.46 for the
fold change, which was the average fold change value of
these miRNAs. Above this threshold, we found another
22 significantly upregulated miRNAs, and miR-19b
ranked first among these. In sum, we obtained 29 signifi-
cantly upregulated miRNAs, and miR-19a/b was at the
top of the list (Additional file 3: Table S3).
RNA isolation and quantitative RT-PCR
Total RNA was extracted from the cultured cells and
tissues using Trizol Reagent (Invitrogen, CA, USA). To
quantify mature miR-19a and 19b, TaqMan miRNA Assay
Probes (Applied Biosystems, Foster City, CA) were used
according to the manufacturer’s instructions. Quantitative
real-time PCR was performed using a TaqMan PCR kit on
an Applied Biosystems 7500 Sequence Detection System
(Applied Biosystems). All of the reactions were run in trip-
licate. After the reactions were complete, the cycle thresh-
old (CT) data were determined using fixed threshold
settings, and the mean CT was determined from triplicate
PCRs. A comparative CT method was used to compare
each condition to the control reactions. U6 snRNA was
used as an internal control, and the relative amount of
miRNA normalized to U6 was calculated with the equa-
tion 2-ΔΔCT in which ΔΔCT = (CT miR-19a − CT U6)tumor
− (CT miR-19a − CT U6)control.
To quantify TIA1 and GAPDH mRNA, oligo d(T)18
primers (TaKaRa) were used to reverse transcribe total
RNA into cDNA. Then, a qRT-PCR was run by using
SYBR Green dye (Invitrogen) and specific primers for
TIA1 and GAPDH. The primer sequences were as follows:
TIA1 (sense): TCCCGCTCCAAAGAGTACATATGAG;
TIA1 (antisense): AAACAATTGCATGTGCTGCACT
TTC; GAPDH (sense): CGAGCCACATCGCTCAGACA;
and GAPDH (antisense): GTGGTGAAGACGCCAG
TGGA. After the reactions were complete, the CT
values were determined by setting a fixed threshold.
The relative amounts of TIA1 mRNAs were normalized
to GAPDH using a method similar to that described
above.
miRNA overexpression and knockdown
miRNA overexpression and knockdown was achieved by
transfecting CRC cells with miRNA mimics or inhibi-
tors, respectively. Synthetic miRNA mimics and inhibi-
tors and scrambled negative control RNAs (control
mimic and inhibitor) were purchased from GenePharma
(Shanghai, China). SW480, Caco2 and HT29 cells were
seeded in 6-well plates and transfected using Lipofecta-
mine 2000 (Invitrogen) on the following day when the
cells were approximately 60–80% confluent. For miRNA
overexpression and knockdown, 200 pmol of miRNA
mimic or inhibitor and corresponding negative control
were added to each well. At 6 h after transfection, the
SW480 and HT29 cell medium was changed to RPMI-
1640 supplemented with 2% FBS, and the Caco2 cell
medium was changed to DMEM supplemented with 2%
FBS. The cells were harvested 48 h after transfection for
total RNA or protein isolation.
Plasmid construction and siRNA interference assay
Mammalian expression plasmids were purchased from
Genescript (Nanjing, China). An empty plasmid served
as a negative control (control plasmid). siRNAs designed
to specifically silence TIA1 or c-MYC were purchased
from GenePharma (Shanghai, China). A scrambled
siRNA served as a control. The siRNA sequences were
as follows: si-TIA1: TGCACAACAAATTGGCCAGTA
and si-c-MYC: ACGGAACTCTTGTGCGTAA. The
overexpression plasmids and siRNAs were transfected
into CRC cells using Lipofectamine 2000 (Invitrogen).
Total RNA and protein were isolated 48 h after trans-
fection and were assessed by quantitative RT-PCR and
western blot, respectively.
Pull-down assay
For miRNA pull-down, SW480 cells which were trans-
fected with biotinylated miR-19a (miR-19a probe) or
control probe (Genescript, Nanjing, China) were har-
vested in lysis buffer (20 mM Tris pH 7.5, 100 mM
KCl, 5 mM MgCl2, 0.5% NP-40 and 1 U/ul Recombin-
ant RNAse inhibitor (TaKaRa)), and the total RNA was
pretreated with DNaseI and then heated at 65 °C for
5 min, followed by an instant ice bath. Then the RNA
was incubated with streptavidin-coated magnetic beads
(New England BioLabs, S1420S) at 4 °C for 4 h, with
constant rotation. After incubation, two washes with
lysis buffer were performed and RNA was extracted
with Trizol (Invitrogen, CA, USA).
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For mRNA pull-down, two DNA probes complemen-
tary to TIA1 mRNA was synthesized with 3’ terminal
biotin labels. A scrambled biotinylated probe was used as
negative control (Genescript, Nanjing, China). The probes
(8 pmol/ul) were then incubated with streptavidin-
coated magnetic beads (New England BioLabs, S1420S)
at 25 °C for 1 h to generate probe-coated magnetic
beads. SW480 cells were harvested in lysis buffer as de-
scribed above. Then the lysate was incubated with
probe-coated beads at 37 °C for 3 h, with constant rota-
tion. After incubation, two washes with lysis buffer
were performed and RNA was extracted with Trizol
(Invitrogen, CA, USA). The sequence of TIA1 probes
were as follows: Probe 1: AAAATCTAAATTTTGCA-
TATT; Probe 2: ATAAGAGAACAATGAGGGTCC.
The extracted RNAs were analyzed by qRT-PCR.
Luciferase reporter assay
An 800-bp fragment of the TIA1 3’-UTR containing the
two conserved miR-19a binding sites was inserted into a
luciferase reporter plasmid (Genescript, Nanjing, China).
To test binding specificity, sequences that interacted
with the miR-19a seed sequence were mutated from
TTGCACA to AACGTGT, and the synthetic TIA1 3’-
UTR mutant fragment was inserted into an equivalent
reporter plasmid (Genescript, Nanjing, China). For the
luciferase reporter assays, SW480 cells were cultured in
24-well plates, and each well was co-transfected with
0.2 μg of firefly luciferase reporter plasmid, 0.2 μg of β-
galactosidase (β-gal) expression plasmid (Ambion), and
equal amounts (50 pmol) of miR-19a mimic, miR-19a
inhibitor or the scrambled negative control RNAs using
Lipofectamine 2000 (Invitrogen). The β-gal plasmid
was used as a transfection efficiency control. The cells
were assayed using a luciferase assay kit 24 h post-
transfection (Promega, Madison, WI, USA).
Cell proliferation assay
For CCK-8 assay, SW480 cells were plated at 2 × 104 cells
per well in 96-well plates and incubated overnight in
RPMI-1640 supplemented with 10% FBS. The cell prolifer-
ation index was measured using a Cell Counting Kit-8
(CK04-500, Dojindo, Japan) at 12, 24, 36, 48, and 60 h
post-transfection according to the manufacturer’s instruc-
tion. Absorbance was measured at a wavelength of 450 nm.
For EdU assay, SW480 cells were seeded in 48-well
plates (Corning). After transfection, when the confluency
of SW480 cells reached 80%, an EdU assay kit (RiBoBio,
Guangzhou, China) was used to determine the prolifera-
tion rate of the cells. The manufacturer’s instruction was
followed except that the nucleus staining dye was chan-
ged from Hoechst 33342 (supplied with the kit) to DAPI
(Beyotime). After staining, the cells were captured by
photomicroscopy (BX51 Olympus, Japan).
Cell migration assay
Cell migration assays were performed using Millipore
24-well Millicell (Millipore) plates containing an 8-μm
pore membrane. The bottom face of the membrane was
coated with 10 μg/mL fibronectin (Gibco). Cells were
harvested 24 h after transfection and suspended in FBS-
free RPMI-1640 culture medium. The cells were then
added to the upper chamber (2 × 104 cells/well), and
0.5 mL RPMI-1640 plus 20% FBS was added to the lower
compartment. The Transwell-containing plates were incu-
bated for 24 h in the incubator. After incubation, cells that
had migrated to the lower surface of the filter membrane
were fixed with 4% paraformaldehyde for 25 min at room
temperature. The membrane was washed 3 times with
PBS and stained with 0.1% crystal violet in methanol for
15 min at room temperature. Cells remaining on the
upper surface of the filter membrane (non-migrating)
were gently scraped off with a cotton swab. The lower sur-
faces (with migrating cells) were captured by photomicro-
scopy (BX51 Olympus, Japan), and the cells were counted
blindly (five fields per chamber).
Immunofluorescence
SW480 cells were seeded on cell slide (Fisherbrand) in
24-well plates and then infected with miR-19a lentivirus
or transfected with TIA1 vector. Two days later the cells
were briefly washed with PBS, and then fixed in 4%
paraformaldehyde for 30 min at room temperature (RT).
After fixation, the cells were washed with PBS (3 ×
5 min, RT), and then permeabilized and blocked using
5% BSA (Sigma) and 0.5% Triton X-100 in PBS for 1 h
at RT. Next, the cells were incubated with primary anti-
body for Ki67 (Abcam, ab16667) in 5% BSA overnight at
4 °C, and then rinsed in PBS (3 × 5 min, RT). The cells
were then incubated in secondary fluorescent antibody
(Invitrogen, 594 nm) in 5% BSA in a light-proof environ-
ment for 1 h at RT. Next, the cells were stained with
DAPI (Beyotime, Shanghai, China) a light-proof environ-
ment for 10 min at RT. Finally the cells were washed
with PBS (3 × 5 min, RT) and visualized using a confocal
microscope (C2+, Nikon).
Colony formation assay
SW480 cells that were infected with miR-19a lentivirus
or transfected with TIA1 vector were suspended in
RPMI-1640 with 0.3% Agarose L.M.P (Biocam) solution,
and plated onto solidified 0.6% Agarose L.M.P in 60 mm
dish (Corning) at a density of 3 × 106 cells/mL in tripli-
cate. The seeded cells were maintained in culture by
feeding with 0.5 ml fresh RPMI-1640 plus 10% FBS and
Penicillin-Streptomycin antibiotics (Gibco) every 3 days,
for a total time 18 days. Then the colonies were fixed
with 4% paraformaldehyde, and stained with 0.05% crys-
tal violet. Then rinse the dish softly to scour off the
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redundant crystal violet. The shapes of colonies were cap-
ture by photomicroscopy (BX51 Olympus, Japan), and the
numbers were counted by visual inspection.
Establishment of tumor xenografts in mice
Four-week-old male SCID mice (nu/nu) were purchased
from the Model Animal Research Center of Nanjing
University (Nanjing, China) and maintained under spe-
cific pathogen-free conditions at Nanjing University. A
lentiviral expression plasmid that can express miR-19a
was purchased from GenePharma (Shanghai, China).
Puromycin (Sigma-Aldrich, USA) was used to success-
fully obtain stably infected cells. SW480 cells were in-
fected with a control lentivirus or a miR-19a lentivirus,
transfected with a TIA1 overexpression plasmid, or co-
transfected with a miR-19a overexpression lentivirus and
a TIA1 overexpression plasmid. After infection and/or
transfection, SW480 cells were subcutaneously injected
into SCID mice (3 × 106 cells in 0.2 mL PBS per mouse,
5 mice per group). The needle was inserted into the left
side of the armpit, midway down, 5 mm deep at a 45°
angle. Mice were sacrificed 24 days after injection to re-
move the xenografted tumors, and the volumes and
weights of the tumors were measured. The volume of
tumors were calculated by the formula: Tumor volume
= [length * (width)2]/2 [35]. A portion of the tissues was
used for protein and total RNA extraction, and the
remaining tissue was fixed in 4% paraformaldehyde for
24 h. The tissue was processed for hematoxylin and
eosin (H&E) staining or immunohistochemical staining
for TIA1 and Ki-67. All experiments were approved by
the Institutional Review Board of Nanjing University
(Nanjing, China) and performed in accordance with the
U.K. Animals (Scientific Procedures) Act (1986) and
the guidelines of the National Institutes of Health.
Statistical analysis
All of the images of the western blot assay, EdU assay,
migration assay, immunofluorescence, colony formation
or animal experiments were representative of at least
three independent experiments or staining results. The
quantitative RT-PCR assay, pull down assay, luciferase
reporter assay, and proliferation assay were performed in
triplicate, and each individual experiment was repeated
several times. The results are presented as the means ±
SE of at least three independent experiments. Observed
differences were considered statistically significant at
p < 0.05 by using Student’s t-test.
Results
TIA1 protein but not mRNA was downregulated in CRC
tissues compared to normal adjacent tissues
First, we examined the expression pattern of TIA1 in
human CRC tissues. In the 16 pairs of CRC tissues and
normal adjacent tissues, we found that TIA1 protein
levels were significantly decreased in CRC tissues com-
pared to normal adjacent tissues (Fig. 1a and b). Similar
TIA1 protein decreases were also observed in lung cancer
Fig. 1 TIA1 protein but not mRNA was downregulated in CRC tissues compared to normal tissues. a and b Western blot analysis of TIA1 protein
levels in 16 paired CRC (T) and normal adjacent tissue (N) samples. a: representative images; b: quantitative analysis. c Quantitative RT-PCR analysis
of TIA1 mRNA levels in the same CRC and normal adjacent tissue sample pairs. d Pearson’s correlation scatter plot of the fold changes of TIA1
protein and mRNA levels in CRC tissue pairs. ***P < 0.001
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(LC) tissues (Additional file 4: Figure S1A and B) and
gastric cancer (GC) tissues (Additional file 4: Figure
S1E and F). However, TIA1 mRNA levels displayed an
irregular alteration (Fig. 1c). We then checked the rele-
vance of the TIA1 protein and mRNA levels by using
Pearson’s correlation scatter plots. The results showed
that there was little correlation between the two levels
(Fig. 1d). The inconsistency between TIA1 protein and
mRNA expression in CRC tissues suggests that there
may exist a post-transcriptional mechanism that down-
regulates the TIA1 protein levels in CRC tissues.
Identification of TIA1 as a direct target gene of miR-19a
Because miRNA is an important and widespread molecule
that post-transcriptionally regulates gene expression, we
hypothesized that TIA1 might be regulated by miRNA.
Because miRNAs and their targets should have opposite
expression pattern changes during tumorigenesis [36] and
TIA1 protein levels were decreased in CRC tissues com-
pared to normal tissues, we tried to identify miRNAs that
are aberrantly increased during CRC transformation. To
achieve this goal, we used an online database YM500 [37,
38] to perform a meta-analysis of the miRNA expression
patterns of 8 normal solid tissues and 429 primary solid
tumors of CRC. Among the 2578 miRNAs analyzed, 128
were found to be significantly upregulated and 145
were downregulated in the solid tumors compared to
the normal tissues (fold change > 2 and p-value < 0.05)
(Additional file 2: Table S2 and Additional file 5: Figure
S2). Then, three computational algorithms, TargetScan
[39], miRanda [40] and PicTar [41], were used in com-
bination to investigate whether the aberrantly increased
miRNAs could potentially target TIA1. Among the 10
most upregulated miRNAs (Additional file 3: Table S3),
miR-19a and miR-19b (miR-19a/b) were identified as
the candidate regulators of TIA1. miR-19a/b belong to
the miR-19 family and only differ by a single nucleotide
at position 11, a region minimally important for target
recognition [42]. Therefore, miR-19a/b generally have
overlapping target genes. The predicted interaction be-
tween miR-19a/b and the target sites in the TIA1 3’-UTR
are illustrated in Fig. 2a and Additional file 6: Figure S3A.
Two predicted hybridizations were identified between miR-
19a/b and the 3’-UTR of TIA1. The minimum free energy
values of the two hybridizations were -18.0 and -19.4 kcal/
mol, and these values are well within the range of genuine
miRNA-target pairs. Furthermore, the miR-19a/b binding
sequences in the TIA1 3’-UTR are highly conserved across
species (Fig. 2a and Additional file 6: Figure S3A).
We next investigated whether miR-19a/b expression
levels were truly inversely correlated with TIA1 expres-
sion in CRC tissues. By measuring miR-19a/b levels in
the same 16 pairs of CRC tissues and corresponding
normal adjacent tissues, we found that miR-19a/b levels
were consistently higher in CRC tissues (Fig. 2b and
Additional file 6: Figure S3B). Furthermore, we illus-
trated the inverse correlation between miR-19a/b and
TIA1 protein levels using Pearson’s correlation scatter
plots. As shown in Fig. 2c and Additional file 6: Figure
S3C, miR-19a expression has a higher inverse correlation
coefficient (R = -0.8224) with TIA1 expression than miR-
19b (R = -0.6425). Thus, although miR-19a/b have simi-
lar sequences, similar expression patterns and the same
binding potential to TIA1, we focused on miR-19a for
further experiments. Then we measured miR-19a level
in LC and GC tissues mentioned above, and we also ob-
served upregulated miR-19a level and reverse correlation
between miR-19a and TIA1 protein levels in the two
cancer types (Additional file 4: Figure S1C, D, G and H).
miR-19a directly regulates TIA1 expression at the post-
transcriptional level
We modulated miR-19a levels in CRC cell lines to investi-
gate whether TIA1 was inversely correlated with miR-19a
in vitro. First, we measured miR-19a and TIA1 protein
levels in three CRC cell lines, SW480, Caco2 and HT29.
As expected, an inverse correlation between miR-19a and
TIA1 expression was observed in these CRC cell lines
(Fig. 3a–c). Next, we efficiently overexpressed or knocked
down the miR-19a level in SW480 cells with a miR-19a
mimic or inhibitor, respectively (Fig. 3d). As anticipated,
TIA1 protein levels dramatically decreased upon miR-19a
overexpression, whereas treatment with the miR-19a in-
hibitor increased TIA1 protein levels (Fig. 3e and f). How-
ever, the alteration of miR-19a had little effect on the
TIA1 mRNA level (Additional file 7: Figure S4A). More-
over, we repeated the above transfection experiments in
two other CRC cell lines (Caco2 and HT29), one LC cell
line (A549) and one GC cell line (MKN) to validate the
robustness of the test. miR-19a repressed TIA1 expression
in all the four cells, too (Fig. 3d–f, Additional file 4: Figure
S1I and J and Additional file 7: Figure S4A).
To validate that miR-19a suppressed TIA1 expression
through direct interaction with the binding site in the
TIA1 3’-UTR, we did pull down assay and luciferase re-
porter assay. Firstly, we performed a biotin-avidin pull-
down assay to assess the direct binding of miR-19a to
TIA1 mRNA. We designed a miR-19a mimic whose 3’
terminal was biotinylated (miR-19a probe). Such modifi-
cation did not affect the suppression of TIA1 by miR-19a
(Additional file 7: Figure S4B and C). After transfecting
miR-19a probe into SW480 for 48 h, we used streptavidin-
coated magnetic beads to pull down biotinylated miR-19a
and measured the co-precipitated TIA1 mRNA. TIA1
mRNA was only enriched in the pull-down product pre-
cipitated by the miR-19a probe and was undetectable in
the product that was precipitated by control probe (Fig. 3g),
suggesting that miR-19a directly binds to TIA1 mRNA in
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SW480 cells. As a control, GAPDH mRNA could not be
detected in the pull-down product precipitated by the
miR-19a probe (Fig. 3g), since GAPDH was not a predicted
target of miR-19a according to the target prediction soft-
wares. Furthermore, we used two biotinylated anti-TIA1
mRNA probes and streptavidin-coated magnetic beads to
pull down TIA1 mRNA fragments and measured the co-
precipitated miR-19a. Anti-TIA1 mRNA probes efficiently
precipitated TIA1 mRNA fragments, as significant enrich-
ment of TIA1 mRNA fragments was detected in the pull-
down products precipitated by the anti-TIA1 mRNA
probes (Additional file 7: Figure S4D). Consequently,
miR-19a was only enriched in the pull-down products
precipitated by the anti-TIA1 mRNA probes and was unot
present in the product precipitated by control probe
(Fig. 3h). As a control, miR-22 could not be detected in
the pull-down products precipitated by the anti-TIA1
mRNA probes (Fig. 3h), since miR-22 was not supposed
to bind TIA1 according to the target prediction software.
To check if it was the predicted seed sequence binding
sites that caused the miRNA-mRNA interaction, we con-
structed a firefly reporter plasmid containing a fragment
of TIA1 3’-UTR across the two conserved miR-19a bind-
ing sites and then transfected the resulting plasmid into
SW480 cells along with the miR-19a mimic, miR-19a in-
hibitor or scrambled negative control RNAs. As expected,
miR-19a overexpression resulted in an approximately 70%
reduction in luciferase reporter activity compared to cells
transfected with the control mimic, whereas miR-19a in-
hibition resulted in a 50% increase in reporter activity
compared to cells transfected with the control inhibitor
(Fig. 3i). Subsequently, we mutated the miR-19a binding
sites in the TIA1 3’-UTR fragment on the reporter
plasmid to eliminate miR-19a binding ability. miR-19a
overexpression or knockdown no longer affected the
mutated reporter activity (Fig. 3i), suggesting that the
binding sites strongly contribute to the miRNA-mRNA
interactions.
Fig. 2 Identification of TIA1 as a miR-19a target. a Schematic description of the hypothetical duplex formed by the interactions between the
binding site in the TIA1 3’-UTR and miR-19a. The miR-19a seed sequence and the seed sequence binding sites in the TIA1 3’-UTR are indicated in red.
All nucleotides of the seed sequence of the binding site are conserved in several species, including human, mouse, rat and rabbit. The predicted free
energy values of the hybrids are indicated. b Quantitative RT-PCR analysis of miR-19a expression levels in the same 16 pairs of CRC and normal tissue
samples. c Pearson’s correlation scatter plot of the fold changes of miR-19a and TIA1 protein in human CRC tissue pairs. ***P < 0.001
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c-MYC, miR-19a, TIA1 and PDCD4 form a regulatory axis
in CRC
As one of the most important oncomiR clusters, the
miR-17-92 cluster is regulated by many upstream tran-
scriptional factors [43]. The best-studied of these factors
is c-Myc [29, 44, 45]. Because c-Myc can transcription-
ally upregulate miR-19a, we speculated that c-Myc also
influences the miR-19a target gene TIA1. We used
siRNA or an overexpression plasmid to silence or en-
hance c-Myc expression in SW480 cells, respectively
(Fig. 4a and b). We observed the anticipated decrease or
increase in miR-19a levels after treatment with c-Myc
siRNA or the overexpression plasmid, respectively
(Fig. 4c). As a consequence, TIA1 protein levels showed
an inverse alteration trend compared to the expression
of c-Myc and miR-19a (Fig. 4a and b). We then trans-
fected SW480 cells with the miR-19a mimic or inhibitor
to reverse the effect of the c-Myc siRNA or overexpres-
sion plasmid on miR-19a, respectively (Fig. 4c). As
expected, TIA1 protein expression was attenuated by co-
treatment with the miR-19a mimic and c-Myc siRNA
compared with treatment with c-Myc siRNA alone. In
Fig. 3 miR-19a directly regulates TIA1 expression at the post-transcriptional level. a Quantitative RT-PCR analysis of miR-19 levels in SW480, Caco2
and HT-29 cells. miR-19 level of SW480 was set as control. b Western blot analysis of TIA1 protein levels in SW480, Caco2 and HT-29 cells. TIA1
level of SW480 was set as control. c Pearson’s correlation scatter plot of the level of miR-19 and TIA1 protein in SW480, Caco2 and HT-29 cells. d
Quantitative RT-PCR analysis of miR-19a levels in SW480, Caco2 and HT-29 cells transfected with control mimic, miR-19a mimic, control inhibitor
or miR-19a inhibitor. e and f Western blot analysis of TIA1 protein levels in SW480, Caco2 and HT-29 cells transfected with control mimic, miR-19a
mimic, control inhibitor or miR-19a inhibitor. e: representative images; f: quantitative analysis. g Quantitative RT-PCR analysis of TIA1 and GAPDH
mRNA levels in SW480 after pulling down with control probe or miR-19a probe; h Quantitative RT-PCR analysis of miR-19a and miR-22 levels in
SW480 after pulling down with control probes or two TIA1 mRNA probes; i The relative luciferase activities in SW480 transfected with wild type
or mutant TIA1 3’-UTR. *P < 0.05; **P < 0.01; ***P < 0.001
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contrast, reduced TIA1 protein expression caused by the
c-Myc overexpression plasmid was rescued by the co-
added miR-19a inhibitor (Fig. 4a and b). To exclude the
possibility that c-Myc directly suppressed TIA1 at the
transcriptional level, we measured the TIA1 mRNA level
after treatment with the c-Myc siRNA or overexpression
plasmid and detected no significant alteration in the
TIA1 mRNA level (Additional file 8: Figure S5A).
TIA1 is an important gene expression modulator, es-
pecially in cancers [10]. We proposed that, by suppress-
ing TIA1, miR-19a also indirectly influences its myriad
downstream targets. PDCD4, an important tumor sup-
pressor in CRC [9], has been reported to be regulated
by TIA1 [46]. We chose PDCD4 as a target to investi-
gate whether miR-19a modulates PDCD4 expression
through regulation of TIA1. First, we screened the full
PDCD4 mRNA (including 5’-UTR, CDS and 3’-UTR)
and identified no miR-19a binding site. Then, we re-
peated the miR-19a mimic and inhibitor transfection
experiment in SW480 cells and measured both the
TIA1 and PDCD4 protein levels. PDCD4 displayed the
same trend in the alteration in the direction of the
TIA1 protein after treatment with the miR-19a mimic
or inhibitor (Fig. 4d and e).
When the TIA1 overexpression plasmid or siRNA (the
efficacies of which were shown in Additional file 8: Figure
S5B–D) was used to neutralize the effects of the miR-19a
mimic or inhibitor on TIA1 expression, respectively, the
PDCD4 levels were also recovered (Fig. 4d and e). We
measured the influence of miR-19a and TIA1 on PDCD4
mRNA levels and verified that miR-19a and TIA1 affected
PDCD4 at the transcriptional level (Fig. 4f). Taken to-
gether, the results reveal that there is a c-MYC-miR-19a-
TIA1-PDCD4 regulatory axis in CRC cells.
miR-19a promotes CRC cell proliferation by targeting TIA1
We hypothesized that miR-19a can promote CRC pro-
gression by suppressing TIA1. Thus, we performed
CCK-8 and EdU assays to investigate the effect of miR-
19a on CRC cell proliferation. SW480 cells transfected
with a miR-19a mimic exhibited increased proliferation; in
contrast, miR-19a inhibition had the opposite effect on
cell proliferation (Fig. 5a–c). Because a single miRNA has
multiple target genes [36], it is necessary to determine
whether the effect of miR-19a on CRC cell proliferation is
derived from miR-19a-mediated TIA1 suppression. We
therefore investigated the exact contribution of the miR-
19a-TIA1 axis on CRC cell proliferation. We used TIA1
Fig. 4 c-MYC, miR-19a, TIA1 and PDCD4 form a regulatory axis in CRC. a and b Western blot analysis of c-Myc and TIA1 protein levels in SW480
cells transfected with control siRNA, si-c-Myc, si-c-Myc plus miR-19a mimic, control plasmid, c-Myc plasmid, or c-Myc plasmid plus miR-19a inhibitor. a:
representative images; b: quantitative analysis. c Quantitative RT-PCR analysis of miR-19a levels in SW480 cells transfected with control siRNA, si-c-Myc,
si-c-Myc plus miR-19a mimic, control plasmid, c-Myc plasmid, or c-Myc plasmid plus miR-19a inhibitor. d and e Western blot analysis of TIA1 and
PDCD4 protein levels in SW480 cells transfected with control mimic, miR-19a mimic, miR-19a mimic plus TIA1 plasmid, control inhibitor, miR-19a
inhibitor, or miR-19a inhibitor plus si-TIA1. d: representative images; e: quantitative analysis. f Quantitative RT-PCR analysis of PDCD4 mRNA levels
in SW480 cells transfected with control mimic, miR-19a mimic, miR-19a mimic plus TIA1 plasmid, control inhibitor, miR-19a inhibitor, or miR-19a
inhibitor plus si-TIA1. ND: Non-Detectable. *P < 0.05; **P < 0.01; ***P < 0.001
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siRNA or an overexpression plasmid to silence or enhance
TIA1 protein expression, respectively. As a result, TIA1
knockdown activated the proliferation of SW480 cells,
whereas TIA1 overexpression had the opposite effect on
cell proliferation (Additional file 9: Figure S6A–D). The
results indicated that miR-19a and TIA1 have opposite
effects on CRC cell proliferation. We then investigated
whether rescuing miR-19a-mediated-TIA1 suppression
with a TIA1 overexpression plasmid attenuates the pro-
proliferation effect of miR-19a on CRC cells. As expected,
cells co-transfected with the miR-19a mimic and TIA1
overexpression plasmid showed lower proliferation rates
Fig. 5 miR-19a promotes CRC cell proliferation by targeting TIA1. a Cell proliferation assays (CCK-8) were performed 12, 24, 36, 48 and 60 h after
the transfection of SW480 cells with equal doses of control mimic, miR-19a mimic, control inhibitor or miR-19a inhibitor. b and c Cell proliferation
assays (EdU) were performed in SW480 cells transfected with equal doses of control mimic, miR-19a mimic, control inhibitor or miR-19a inhibitor.
b: representative images; c: quantitative analysis. d Cell proliferation assays (CCK-8) were performed 12, 24, 36 and 48 and 60 h after transfection
of SW480 cells with equal doses of control mimic plus control plasmid, miR-19a mimic plus control plasmid, control mimic plus TIA1 overexpression
plasmid, or miR-19a mimic plus TIA1 overexpression plasmid. e and f Cell proliferation assays (EdU) were performed in SW480 cells transfected with
equal doses of control mimic plus control plasmid, miR-19a mimic plus control plasmid, control mimic plus TIA1 overexpression plasmid, or miR-19a
mimic plus TIA1 overexpression plasmid. e: representative images; f: quantitative analysis. **P < 0.01; ***P < 0.001
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compared to cells transfected with the miR-19a mimic
alone (Fig. 5d–f ). Thus, restoration of TIA1 expression
can reverse miR-19a-induced cell proliferation, suggesting
that targeting TIA1 is one mechanism by which miR-19a
exerts its oncomiR function.
miR-19a promotes CRC cell migration by targeting TIA1
Next, we performed a Transwell assay to investigate the
effect of miR-19a on CRC cell migration. Similar to the ef-
fect on SW480 proliferation, miR-19a promoted SW480
migration (Fig. 6a and b). We then validated that the pro-
motion of cell migration by miR-19a was a result of the in-
hibition of TIA1. SW480 cells transfected with TIA1
siRNA showed increased cell migration; in contrast, trans-
fection with the TIA1 overexpression plasmid had the op-
posite effect on cell migration (Additional file 9: Figure
S6E and F). Moreover, compared with cells transfected
with miR-19a mimic alone, those transfected with both
the miR-19a mimic and TIA1 overexpression plasmid ex-
hibited a significantly lower migration rate (Fig. 6a and c),
suggesting that miR-19a-resistant TIA1 is sufficient to
rescue the suppression of TIA1 through miR-19a and
attenuate the pro-migration effect of miR-19a on CRC
cells. Taken together, these data revealed that miR-19a
promotes CRC cell migration by silencing TIA1.
miR-19a promotes CRC growth in vivo by targeting TIA1
Finally, we investigated the effects of miR-19a and TIA1
on the growth of CRC xenografts in nude mice. To pre-
pare the nude mouse xenograft model, we first infected
SW480 cells with a miR-19a overexpression lentivirus,
transfected SW480 cells with a TIA1 overexpression
plasmid, or co-transfected SW480 cells with the miR-
19a overexpression lentivirus and TIA1 overexpression
plasmid. The upregulation of miR-19a and consequential
suppression of TIA1 protein by lentivirus infection are
shown in Additional file 10: Figure S7A–C. We then ex-
amined the effect of miR-19a lentivirus or TIA1 vector
on SW480 proliferation and malignancy. Ki-67 immuno-
fluorescence and soft-agar colony formation assay results
indicated that miR-19a could promote SW480 cells pro-
liferation and anchorage-independent growth by target-
ing TIA1 (Fig. 7a and b, Additional file 10: Figure S7D–
F). Next, we subcutaneously implanted the infected or
transfected SW480 cells into 4-week-old nude mice. We
evaluated tumor growth 24 days after cell implantation.
The volumes or weights of xenografted tumors were
smaller or lower in the control group than in the miR-
19a-overexpressing group but larger or higher than in
the TIA1-overexpressing group, respectively (Fig. 7c–e).
The overexpression of TIA1 attenuated the growth-
Fig. 6 miR-19a promotes CRC cell migration by targeting TIA1. a–c Cell migration assays (Transwell) were performed in SW480 cells that were
transfected with equal doses of control mimic, miR-19a mimic, control inhibitor or miR-19a inhibitor (upper panel), or with equal doses of
control mimic plus control plasmid, miR-19a mimic plus control plasmid, control mimic plus TIA1 overexpression plasmid, or miR-19a mimic
plus TIA1 overexpression plasmid (lower panel). a: representative images; b and c: quantitative analysis of the number of migrated cells.
*P < 0.05; **P < 0.01
Liu et al. Molecular Cancer  (2017) 16:53 Page 11 of 17
Fig. 7 (See legend on next page.)
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promoting effects of miR-19a, suggesting that miR-19a
promotes tumor growth by silencing TIA1 (Fig. 7c–e).
We next isolated and analyzed total RNA and protein
from the tumors. Significant upregulation of miR-19a or
TIA1 was observed in the miR-19a-overexpressing or
TIA1-overexpressing groups, respectively, and TIA1
overexpression could truly reverse the inhibition effect
of miR-19a on TIA1 (Additional file 10: Figure S7G–I).
We then embedded xenografted tumors in paraffin and
performed H&E staining or examined the tumors using
immunohistochemical assays. H&E results showed in-
creased cell mitosis in the miR-19a-overexpressing group
and decreased mitosis in the TIA1-overexpressing group,
whereas xenografts with both miR-19a and TIA1 over-
expression exhibited less cell mitosis compared to xe-
nografts with miR-19a overexpression alone (Fig. 7f ).
Immunohistochemical staining revealed lower TIA1
and higher Ki-67 levels in tumors from the miR-19a-
overexpressing group, whereas tumors from the TIA1-
overexpressing group showed increased TIA1 and de-
creased Ki-67 levels (Fig. 7f–h). TIA1 overexpression
in the miR-19a lentivirus-infected group restored the
suppression of TIA1 and Ki-67 caused by miR-19a
overexpression (Fig. 7f–h). These results are consistent
with the in vitro findings, which firmly validated the
oncomiR role of miR-19a in CRC tumorigenesis through
targeting TIA1.
Discussion
In 2016, the American Cancer Society estimated that
there would be more than 130,000 new cases of and
more than 49,000 new deaths from CRC in the United
States, making it the third leading cause of death from
cancer [1]. Although recent advances in medicine have
improved the survival of CRC patients, CRC remains a
major public health problem. The clinical behavior of
colorectal cancer results from interactions at many levels
[2], and among these interactions, the genetic changes in
oncogenes and/or tumor-suppressor genes are the most
important driving force for tumorigenesis and cancer
development. TIA1 is an important tumor suppressor in
many cancers [10], especially in CRC [15, 16]. In this
study, we demonstrated that TIA1 protein was signifi-
cantly downregulated in CRC tissues and inhibited pro-
liferation and migration of CRC cells and attenuated
tumor growth in xenografted mice. Interestingly, we
observed that TIA1 mRNA levels did not exhibit alter-
ations consistent with the protein levels. This phenomenon
inspired us to speculate that a post-transcriptional mech-
anism is involved in the repression of TIA1 expression in
CRC. Therefore, we focused on a vital post-transcriptional
regulator, miRNA, and provided the first evidence sup-
porting the important role of miR-19a as an oncomiR in
CRC targeting TIA1.
The discovery of miRNAs expanded the list of classical
tumor suppressors and oncogenes. miRNA profiles
undergo a wide array of alterations during the initiation
and development of various types of cancer, including
CRC [47–49]. More importantly, new studies have estab-
lished the potential usefulness of miRNAs as therapeutic
molecules against cancer [50–53]. For example, aber-
rantly dysregulated miRNAs can be restored by using
antagomirs or miRNA mimics [50, 53]. miR-19a belongs
to a well-known oncomiR cluster, namely the miR-17-92
cluster. miR-19a has been widely studied and is thought
to be a key oncogenic component of mir-17-92 [54].
miR-19a is overexpressed and functions as an oncomiR
in many cancer types, including bladder cancer [55],
cervical cancer [56], gastric cancer [57], pancreatic can-
cer [58], renal cancer [59], lung cancer [60] and CRC
[32–34]. In this study, we performed a meta-analysis of
the miRNA expression profile in CRC and found that
some miRNAs (especially miR-19a) were dramatically
upregulated. We then used 3 bioinformatic algorithms
to predict miRNAs that could target TIA1 and identi-
fied miR-19a as an ideal candidate. Subsequently, we
experimentally validated TIA1 as a genuine miR-19a
target in three CRC cell lines. Furthermore, we revealed
the important effects of miR-19a-driven suppression of
TIA1 on the promotion of CRC cell proliferation and
migration and on tumor growth in a xenografted nude
mouse model. These results suggested that targeting
miR-19a may be a practical method to control CRC de-
velopment and ameliorate symptoms, as has been
shown by other groups [50, 51, 53]. More research
should focus on characterizing the feasibility of target-
ing miR-19a in CRC therapy and developing simplified
and cost-effective manipulation methods.
The c-Myc oncogene contributes to the genesis of many
human cancers [61, 62], including CRC [63]. c-Myc
functions as a transcriptional activator or inhibitor that
modulates almost every aspect of tumor cell biology
(See figure on previous page.)
Fig. 7 miR-19a promotes CRC growth in vitro and in vivo by targeting TIA1. a and b Colony formation assays of SW480 cells infected with
miR-19a lentivirus, transfected with TIA1 vector or both. a: Representative images of colony formation assays; b: quantitative analysis of the
numbers of colonies. c Representative images of tumors from the implanted mice. d and e Quantitative analysis of xenografted tumor volume
and weight. d: tumor volume; e: tumor weight. f–h H&E-stained sections and immunohistochemical staining for TIA1 and Ki-67 in tumors from
implanted mice. f: representative images; g and h: quantitative analysis. i Working model of the c-Myc-miR-19a-TIA1-PDCD4 regulatory axis in
CRC. **P < 0.01; ***P < 0.001
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[64]. In recent years, the ability of c-Myc to regulate
miRNAs has received much attention [65]. Many of the
functions of c-Myc in cancers are executed through its
downstream miRNAs [66]. Among the miRNA targets
of c-Myc, the miR-17-92 cluster is the most well-studied
[29, 44, 45]. c-Myc has been shown to upregulate the ex-
pression of the mir-17-92 cluster to accelerate tumor de-
velopment in a mouse B-cell lymphoma model [29].
Increased expression of the miR-17-92 cluster during
colorectal adenoma to adenocarcinoma progression is
also associated with c-Myc expression [45]. Interestingly,
c-Myc influences its target miRNAs to indirectly regu-
late the target genes of the miRNAs. For example, the c-
Myc-regulated miR-17-92 cluster can modulate E2F1
expression to promote cell cycle progression [44]. In this
study, we showed that c-Myc indirectly suppresses TIA1
expression through enhancing miR-19a expression in
CRC. These findings provide new insights into under-
standing how c-Myc contributes to CRC development.
In addition, another member of the TIA family, T-cell
intracellular antigen 1 (TIA1)-related protein (TIAR), in-
hibits translation of c-Myc mRNA via AU-rich elements
[67]. This finding, combined with ours, reveals the com-
plex relationship between c-Myc and TIA family.
As an important gene expression modulator, TIA1 reg-
ulates many downstream genes [10]. Under conditions
of rapid oxygen decline and extreme hypoxia, TIA1 co-
aggregates with TIAR to suppress the HIF-1α pathway
[68]. TIA1 can also function as a translational silencer of
COX-2 expression in neoplasia [69]. Moreover, TIA1
even affects the expression of some miRNAs [70]. It is
easy to speculate that by suppressing TIA1, miR-19a
may also influence the downstream genes of TIA1. In
this study, we proved that miR-19a inhibits TIA1 to in-
directly downregulate PDCD4, which is a TIA1 target
[46] as well as an important tumor suppressor [9] in
CRC. Some oncomiR functions of miR-19a may be indir-
ectly executed by inhibiting its indirect target PDCD4.
Thus, TIA1 functions as a bridge to link upstream regu-
lators (such as miR-19a) and downstream effectors (such
as PDCD4). We suppose that there are many other in-
direct regulation relationships similar to miR-19a and
PDCD4, and these relationships greatly complicate the
miR-19a—target regulatory network.
Conclusions
In summary, this study demonstrated for the first time that
miR-19a can target TIA1 to promote CRC tumorigenesis,
and we identified the c-MYC—miR-19a—TIA1—PDCD4
axis in CRC (The working model was shown in Fig. 7i).
More research should be conducted on miR-19a and
TIA1, and we would like to further elucidate the molecular
mechanisms of CRC and develop new approaches for
molecular therapeutics for this disease.
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tissues from a meta-analysis using YM500. (XLSX 47 kb)
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Additional file 4: Figure S1. miR-19a can also target TIA1 in LC and
GC tissues and cell lines. (A and B) Western blot analysis of TIA1
protein levels in 8 paired LC (T) and normal adjacent tissue (N) samples.
A: representative images; B: quantitative analysis. (C) Quantitative
RT-PCR analysis of miR-19a levels in the same LC and normal adjacent
tissue sample pairs. (D) Pearson’s correlation scatter plot of the fold
changes of TIA1 protein and miR-19a levels in LC tissue pairs. (E and
F) Western blot analysis of TIA1 protein levels in 11 paired GC (T)
and normal adjacent tissue (N) samples. E: representative images; F:
quantitative analysis. (G) Quantitative RT-PCR analysis of miR-19a
levels in the same GC and normal adjacent tissue sample pairs. (H)
Pearson’s correlation scatter plot of the fold changes of TIA1 protein
and miR-19a levels in GC tissue pairs. (I and J) Western blot analysis
of TIA1 protein levels in A549 and MKN cells transfected with control
mimic, miR-19a mimic, control inhibitor or miR-19a inhibitor. E:
representative images; F: quantitative analysis. *P < 0.05; **P < 0.01;
***P < 0.001. (TIF 1406 kb)
Additional file 5: Figure S2. Profiles of 273 significantly changed
miRNAs in 429 primary solid colon tumors and 8 normal solid tissues
from a meta-analysis by using YM500. Detailed information on these miR-
NAs is listed in Additional file 2: Table S2. (TIF 1762 kb)
Additional file 6: Figure S3. miR-19b can also regulate TIA1 expression
in CRC. (A) Schematic description of the hypothetical duplex formed
by the interaction between the binding site in the TIA1 3’-UTR and
miR-19b. The miR-19b seed sequence and the seed sequence binding
sites in the TIA1 3’-UTR are indicated in red. All nucleotides of the
seed sequence of the binding site are conserved in several species,
including human, mouse, rat and rabbit. The predicted free energy
values of the hybrids are indicated. (B) Quantitative RT-PCR analysis
of miR-19b expression levels in the same 16 pairs of CRC and normal
tissue samples. (C) Pearson’s correlation scatter plot of the fold change
of miR-19b and TIA1 protein in human CRC tissue pairs. (D) Quantitative
RT-PCR analysis of miR-19b levels in SW480 cells transfected with
control mimic, miR-19b mimic, control inhibitor or miR-19b inhibitor.
(E and F) Western blot analysis of TIA1 protein levels in SW480 cells
transfected with control mimic, miR-19b mimic, control inhibitor or
miR-19b inhibitor. E: representative images; F: quantitative analysis.
***P < 0.001. (TIF 917 kb)
Additional file 7: Figure S4. Effect of miR-19a on TIA1 mRNA level and
the efficacies of miR-19a probe and TIA1 mRNA probes. (A) Quantitative
RT-PCR analysis of TIA1 mRNA levels in SW480, Caco2 and HT-29 cells
transfected with control mimic, miR-19a mimic, control inhibitor or
miR-19a inhibitor. (B and C) Western blot analysis of TIA1 protein levels
in SW480 cells transfected with control mimic, miR-19a mimic or
biotinylated miR-19a mimic. B: representative images; C: quantitative
analysis. (D) Quantitative RT-PCR analysis of TIA1 and GAPDH mRNA
levels in SW480 after pulling down with control probe or TIA1 mRNA
probes. **P < 0.01; ***P < 0.001. (TIF 371 kb)
Additional file 8: Figure S5. Effect of c-Myc on TIA1 mRNA level and
the efficacies of TIA1 siRNA and overexpression vector. (A) Quantitative
RT-PCR analysis of TIA1 mRNA levels in SW480 cells transfected with
control siRNA, si-c-Myc, control plasmid or c-Myc plasmid. (B and C)
Western blot analysis of TIA1 protein levels in SW480 cells transfected
with control siRNA, si-TIA1, control vector or TIA1 vector. B: representative
images; C: quantitative analysis. (D) Quantitative RT-PCR analysis of
TIA1 mRNA levels in SW480 cells transfected with control siRNA, si-TIA1,
control vector or TIA1 vector. ***P < 0.001. (TIF 602 kb)
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Additional file 9: Figure S6. Effects of TIA1 on SW480 proliferation and
migration. (A and B) Cell proliferation assays (CCK-8) were performed 12,
24, 36, 48 and 60 h after the transfection of SW480 cells with equal doses
of control siRNA, si-TIA1, control plasmid or TIA1 plasmid. (C and D) Cell
proliferation assays (EdU) were performed in SW480 cells transfected
with equal doses of control siRNA, si-TIA1, control plasmid or TIA1
plasmid. C: representative images; D: quantitative analysis. (E and F) Cell
migration assays (transwell) were performed in SW480 cells that were
transfected with equal doses of control siRNA, si-TIA1, control plasmid
or TIA1 plasmid. E: representative images; F: quantitative analysis. *P < 0.05;
**P < 0.01; ***P < 0.001. (TIF 4077 kb)
Additional file 10: Figure S7. The efficiency of miR-19a lentivirus and
TIA1 vector on TIA1 protein level and SW480 proliferation. (A) Quantitative
RT-PCR analysis of miR-19a levels in SW480 cells, which were infected with a
control lentivirus or a lentivirus to overexpress miR-19a. (B and C) Western
blot analysis of TIA1 protein levels in SW480 cells, which were infected with
a control lentivirus or a lentivirus to overexpress miR-19a. B: representative
images; C: quantitative analysis. (D-F) miR-19a could promote SW480 cell
proliferation by targeting TIA1 in vitro. D representative images of Ki67
immunofluorescence; E: quantitative analysis of Ki67 immunofluorescence;
F: representative images of formed SW480 colonies. (G) Quantitative RT-
PCR analysis of miR-19a levels in tumors from implanted mice. (H and I)
Western blot analysis of TIA1 protein levels in tumors from implanted
mice. H: representative images; I: quantitative analysis. **P < 0.01; ***P < 0.001.
(TIF 3290 kb)
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